Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Phase 4

• Conditions: Ssri; Neuronal Plasticity
• Interventions: Drug: Placebo; Drug: Escitalopram; Other: 3xMR scan (fMRI, DTI, strucutral MRI); Behavioral: Association learning paradigm; Behavioral: Association re-learning paradigm

• Registration Number: NCT02753738
• Lead Sponsor: Medical University of Vienna

Brief Summary

Background:

Conclusive evidence states that the serotonergic system mediates neuroplasticity from early embryonic development until brain maturation in adulthood. This study aims to demonstrate that selective serotonin reuptake inhibitors (SSRIs) enhance learning-dependent neuroplasticity in vivo, hereby contributing to the investigators understanding of the mechanism of action of therapy with SSRIs.

Objectives:

1. To prove a positive influence of SSRIs on structural remodeling during learning, reflected by enhancements of gray and white matter microstructure, connectivity and functionality in brain regions involved in learning processes.

2. To show that this effect is topologically specific, i.e. that enhancements of plasticity markers are found in different regions depending on their involvement during the performance of specific learning tasks.

Study design:

Randomized, double-blind, placebo-controlled, longitudinal mono-center study. 80 healthy subjects will undergo three MRI scanning sessions: 1. baseline, at study entry, 2. after 3 weeks of facial/emotional (n=40) or Chinese character-meaning learning (n=40) and 3. after 3 weeks learning of new associations under administration of an SSRI or placebo.

Methods:

MRI measurements will be performed on a 3 Tesla PRISMA MAGNETOM MR scanner. Changes in gray matter microstructure will be assessed using high-resolution structural MRI and analyzed with voxel-based morphometry (VBM). Diffusion tensor imaging (DTI) enables non-invasive investigation of neuroplasticity in the human brain based on the reduction in mean diffusivity associated with swelling of astrocytes after increased synaptic activity. Resting-state functional MRI (fMRI) will allow for the measurement of changes in functional coupling between brain regions, and fMRI during tasks will assess differential activity in brain regions during learning.

Relevance and implications:

This study aims to provide evidence that SSRIs facilitate cytoarchitectonical restructuring. In addition to expanding the investigators current knowledge on the trophic effects of SSRIs, the results of this study will also elucidate interactions between the serotonergic system and changes to neuronal networks during learning as well as their behavioral consequences. By probing the neurobiological correlates of the antidepressant and anti-anxiety effects of SSRIs, this study will provide a rationale for targeted interventions that harness the neuroplasticity enhancing properties of SSRIs to facilitate therapeutic processes.

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-04
• Study First Submitted: 2016-04-21
• Study First Submitted QC: 2016-04-25
• Last Update Submitted: 2016-04-25
• Study First Posted: 2016-04-28
• Last Update Posted: 2016-04-28
• Study Start: 2016-08
• Primary Completion: 2019-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID)
• Willingness and competence to sign the informed consent form
• Right-handedness
• Non-smoker, and non-alcohol drinker

Read More

Exclusion Criteria

• Any medical, psychiatric or neurological illness
• Current or former substance abuse
• Any implant or stainless steel graft or any other contraindications for MRI
• First degree relatives with a history of psychiatric illness or substance abuse
• Color blindness, any Chinese language skills
• Failure to comply with the study protocol or to follow the instructions of the investigating team
• Lifetime use of SSRIs or related psychotropic agents
• Non-Caucasian

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo treatment	Placebo	Subjects will receive 21 days of placebo treatment while performing learning paradigms.
SSRI treatment	Escitalopram	Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
SSRI treatment	3xMR scan (fMRI, DTI, strucutral MRI)	Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
SSRI treatment	Association learning paradigm	Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
SSRI treatment	Association re-learning paradigm	Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
Placebo treatment	3xMR scan (fMRI, DTI, strucutral MRI)	Subjects will receive 21 days of placebo treatment while performing learning paradigms.
Placebo treatment	Association learning paradigm	Subjects will receive 21 days of placebo treatment while performing learning paradigms.
Placebo treatment	Association re-learning paradigm	Subjects will receive 21 days of placebo treatment while performing learning paradigms.

Primary Outcome Measures

Name	Time	Method
Gray matter volume	21 days	voxel based morphometry (T1 weighted MPRAGE sequence)
Mean diffusivity	21 days	diffusion tensor imaging

Secondary Outcome Measures

Name	Time	Method
BOLD signal	21 days	functional MRI (learning paradigms)

Trial Locations

Locations (1)

Department of Psychiatry and Psychotherapy, Medical University of Vienna; 🇦🇹 Vienna, Austria